ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AQST

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. for the period between June 16, 2025, and January 8, 2026, due to alleged misleading statements regarding the company's New Drug Application for Anaphylm [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Aquestive made false and/or misleading statements and failed to disclose the true state of its New Drug Application for Anaphylm, particularly regarding the human factors involved in the use of its sublingual film [5]. - Investors who purchased Aquestive securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 4, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].